Boehringer’s Cyltezo, The Only Interchangeable Humira Biosimilar, Gets A New Form
Subcutaneous Form Has Been FDA-Approved Since 2017; Interchangeable Since 2021
Boehringer Ingelheim has welcomed a new FDA approval for its Cyltezo (adalimumab-adbm) interchangeable biosimilar, ahead of planned launch on 1 July.
